EVALUATION OF BOTANICALS FOR H .PYLORI INFECTIONS

描述(申请人摘要)：经过十多年的研究和 争议，已经确凿地证明幽门螺杆菌是 消化性溃疡疾病的主要原因。世界各地的高感染率 造成严重的健康和经济问题。仅在美国，就有50万新的 病例，每年报告复发400万例，费用为3至4美元 十亿美元。目前治疗幽门螺杆菌感染的方法包括 抗生素和H2阻滞剂的组合。然而，由于严重的 不良反应，患者依从性低，导致发展 抗生素耐药性。因此，治疗幽门螺杆菌的新方法 感染是迫切需要的。几千年来，传统的制度 已成功地将植物性药物(植物性药物)用于 治疗消化不良、胃炎、消化性溃疡。然而，这些中的大多数 植物类药物尚未被系统地筛选出抗H.幽门螺杆菌活性。 这份提案描述了一种国际化的、多学科的方法 植物提取物治疗和预防幽门螺杆菌的研究 感染。这项工作旨在产生足够的初步数据来 作为更明确的研究的基础。该项目的主要目标是 鉴定和标准化植物提取物和提取物的组合 幽门螺杆菌感染的治疗。为了实现这一目标，该项目 涉及(1)选择和采购待测试的植物药物(2) 来源材料的提取，(3)短期体外和FN体内试验 确定活动性和机制信息的生物学研究(4) 活体评估以确定安全性和有效性，以及(5)测定 有效提取物标准化的主要化学成分。完毕 在为期两年的时间里，将选出大约60种新的植物药物，并 评估对幽门螺杆菌的抗菌活性。HIGH列表 将根据以下数据分析生成用于测试的优先植物药物 Naprlartsm数据库、Medline、德国委员会E专著和其他 数据源。这种植物选择方法的成功体现在我们的 初步结果，对25种已确认的植物性药物进行了初步测试，结果显示 13种活性提取物。在这个项目中，植物药将被采购和 准备好的摘录。植物提取物将在体外进行 使用15个幽门螺杆菌菌株的生物测定方案。活性提取物将被利用 用于活体研究。长期目标是发展安全和有效的 治疗和预防幽门螺杆菌感染的植物提取物。

DESCRIPTION (Applicant's Abstract): After more than a decade of research and controversy, it has been conclusively demonstrated that Helicobacter pylori is the main cause of peptic ulcer disease. High infection rates around the world pose serious health and economic problems. In the U. S. alone, 500,000 new cases, and 4 million recurrences are reported annually, at a cost of $3 to $4 billion dollars. Current therapies for H. pylori infections consist of combinations of antibiotics, and H2 blockers. However, due to the serious adverse reactions, patient compliance is low, leading to the development of antibiotic resistance. Thus, new approaches to the treatment H. pylori infections are urgently needed. For thousand of years traditional systems of medicine have successfully used botanicals (plant-based medicines) for the treatment of dyspepsia, gastritis and peptic ulcers. However, most of these botanicals have not been systematically screened for anti-H. pylori activity. This proposal describes an international, multidisciplinary approach to investigating botanical extracts for the treatment and prevention of H. pylori infections. The work is designed to generate sufficient preliminary data to serve as the basis of more definitive studies. The major goal of the project is to identify and standardize botanical extracts and combinations of extracts for the treatment of H. pylori infections. To accomplish this goal, the project involves (1) selection and procurement of botanicals to be tested (2) extraction of the source materials, (3) short-term in vitro and fn vivo testing biological studies to determine activity and mechanistic information (4) in vivo evaluations to establish safety and efficacy, and (5) determination of the major chemical constituents for standardization of the active extracts. Over the two-year period, approximately 60 new botanicals will be selected and evaluated for antibacterial activity against H. pylori. The list of high priority botanicals for testing will be generated based on data analysis from the Napralertsm database, Medline, German Commission E Monographs and other data sources. The success of this method for plant selection is seen in our preliminary results where an initial testing of 25 identified botanicals led to 13 active extracts. In this project, the botanicals will be procured and extracts prepared. The botanical extracts will be subjected to in vitro bioassay protocols using 15 H. pylori strains. Active extracts will be utilized for in vivo studies. The long-term objectives are to develop safe and effective botanical extracts for the treatment and prevention of H. pylori infections.